GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » Debt-to-Equity

Beijing Luzhu Biotechnology Co (HKSE:02480) Debt-to-Equity : 0.08 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co Debt-to-Equity?

Beijing Luzhu Biotechnology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$1.94 Mil. Beijing Luzhu Biotechnology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$70.16 Mil. Beijing Luzhu Biotechnology Co's Total Stockholders Equity for the quarter that ended in Dec. 2024 was HK$911.36 Mil. Beijing Luzhu Biotechnology Co's debt to equity for the quarter that ended in Dec. 2024 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Beijing Luzhu Biotechnology Co's Debt-to-Equity or its related term are showing as below:

HKSE:02480' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.02   Med: 0.02   Max: 0.08
Current: 0.08

During the past 4 years, the highest Debt-to-Equity Ratio of Beijing Luzhu Biotechnology Co was 0.08. The lowest was -0.02. And the median was 0.02.

HKSE:02480's Debt-to-Equity is ranked better than
62.92% of 1014 companies
in the Biotechnology industry
Industry Median: 0.14 vs HKSE:02480: 0.08

Beijing Luzhu Biotechnology Co Debt-to-Equity Historical Data

The historical data trend for Beijing Luzhu Biotechnology Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Luzhu Biotechnology Co Debt-to-Equity Chart

Beijing Luzhu Biotechnology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
-0.02 0.01 0.02 0.08

Beijing Luzhu Biotechnology Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Equity Get a 7-Day Free Trial 0.01 0.02 0.02 0.03 0.08

Competitive Comparison of Beijing Luzhu Biotechnology Co's Debt-to-Equity

For the Biotechnology subindustry, Beijing Luzhu Biotechnology Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beijing Luzhu Biotechnology Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Luzhu Biotechnology Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Beijing Luzhu Biotechnology Co's Debt-to-Equity falls into.


;
;

Beijing Luzhu Biotechnology Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Beijing Luzhu Biotechnology Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.943 + 70.16) / 911.355
=0.08

Beijing Luzhu Biotechnology Co's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.943 + 70.16) / 911.355
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Luzhu Biotechnology Co  (HKSE:02480) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Beijing Luzhu Biotechnology Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Beijing Luzhu Biotechnology Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Luzhu Biotechnology Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » Debt-to-Equity
Comparable Companies
HKSE:02256 HKSE:02315 HKSE:01477 HKSE:02105 HKSE:06955 HKSE:06660 HKSE:01672 HKSE:02616 HKSE:02179 HKSE:09966 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN
Website
http://www.luzhubiotech.com
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is its Core Product.
Executives
Kong Jian 2101 Beneficial owner
Zhang Yanping 2202 Interest of your spouse
Ma Jianan 2201 Interest of corporation controlled by you
Zhu Hai Heng Qin Lv Zhu Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Bei Jing Lv Zhu Kang Rui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Bei Jing Sai Sheng Yao Ye Gu Fen You Xian Gong Si 2101 Beneficial owner
Bei Jing Yi Zhuang Er Qi Sheng Wu Yi Yao Chan Ye Tou Zi Ji Jin You Xian He Huo 2101 Beneficial owner
Bei Jing Yi Zhuang Sheng Wu Yi Yao Bing Gou Tou Zi Zhong Xin You Xian He Huo 2101 Beneficial owner
Tian Jin Sai Ding Fang De Zi Chan Guan Li Zhong Xin 2201 Interest of corporation controlled by you
Tian Jin Sai De Rui Bo Zi Chan Guan Li Zhong Xin 2201 Interest of corporation controlled by you
Bei Jing Yi Tang Sai Ying Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
China Construction Bank Corporation 2201 Interest of corporation controlled by you
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Peng Ling 2201 Interest of corporation controlled by you
Ma Biao 2201 Interest of corporation controlled by you

Beijing Luzhu Biotechnology Co Headlines

No Headlines